Canaccord raises Amgen stock price target on strong quarter, pipeline wins
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- AMGN Amgen+14.9% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Amgen belongs to, so it often moves with news about it.
- GILD Gilead Sciences+17.7% 30d
Gilead Sciences is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+29.2% 30d
Moderna is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-11.9% 9d
argenx SE is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
- BIIB Biogen+13.7% 30d
Biogen is a peer of Amgen in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| AMGN | -2.03% | +1.07% | base | +3.67% | -0.14% | +0.04% | +0.88% |
| XLV | -2.31% | +0.48% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| GILD | -4.93% | +2.07% | base | +4.16% | +0.01% | +0.06% | +1.13% |
| MRNA | -6.29% | -2.97% | base | +13.13% | +5.69% | +15.32% | +17.78% |
| ARGX | -1.09% | -0.93% | base | +3.36% | -0.78% | +2.34% | +6.90% |
| RVMD | -2.84% | -1.45% | base | +2.75% | -8.41% | +0.17% | +3.13% |
| BIIB | -1.90% | +1.86% | base | +2.22% | -2.02% | -0.22% | +2.40% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Canaccord raises Amgen stock price target on strong quarter, pipeline wins Investing.com
Source: Investing.com
Energy
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | +3.67% | final price |
| AMGN | the next day | -0.14% | final price |
| AMGN | two days later | +0.04% | final price |
| AMGN | three days later | +0.88% | final price |
| AMGN | three days earlier | +1.07% | final price |
| AMGN | five days earlier | -2.03% | final price |
| ARGX | that day | +3.36% | final price |
| ARGX | the next day | -0.78% | final price |
| ARGX | two days later | +2.34% | final price |
| ARGX | three days later | +6.90% | final price |
| ARGX | three days earlier | -0.93% | final price |
| ARGX | five days earlier | -1.09% | final price |
| BIIB | that day | +2.22% | final price |
| BIIB | the next day | -2.02% | final price |
| BIIB | two days later | -0.22% | final price |
| BIIB | three days later | +2.40% | final price |
| BIIB | three days earlier | +1.86% | final price |
| BIIB | five days earlier | -1.90% | final price |
| GILD | that day | +4.16% | final price |
| GILD | the next day | +0.01% | final price |
| GILD | two days later | +0.06% | final price |
| GILD | three days later | +1.13% | final price |
| GILD | three days earlier | +2.07% | final price |
| GILD | five days earlier | -4.93% | final price |
| MRNA | that day | +13.13% | final price |
| MRNA | the next day | +5.69% | final price |
| MRNA | two days later | +15.32% | final price |
| MRNA | three days later | +17.78% | final price |
| MRNA | three days earlier | -2.97% | final price |
| MRNA | five days earlier | -6.29% | final price |
| RVMD | that day | +2.75% | final price |
| RVMD | the next day | -8.41% | final price |
| RVMD | two days later | +0.17% | final price |
| RVMD | three days later | +3.13% | final price |
| RVMD | three days earlier | -1.45% | final price |
| RVMD | five days earlier | -2.84% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.65% | final price |
| XLV | two days later | +0.47% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 20 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 43 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 70 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 86 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 68 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Biogen (BIIB), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Biogen (BIIB) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Biogen (BIIB), worth $1,001 - $15,000 on 18 Aug 2026. That is 78 days before publication. Filed 1 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid the energy case looks
12 out of 100
“Canaccord raises Amgen stock price target on strong quarter, pipeline wins” scores 12 out of 100. The score uses 1 sources.